Exact Mass: 384.1219

Exact Mass Matches: 384.1219

Found 35 metabolites which its exact mass value is equals to given mass value 384.1219, within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error 0.0002 dalton.

S-adenosylhomocysteine (SAH)

(2S)-2-Amino-4-({[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulphanyl)butanoic acid

C14H20N6O5S (384.1216)


S-Adenosyl-L-homocysteine (SAH) is formed by the demethylation of S-adenosyl-L-methionine. S-Adenosylhomocysteine (AdoHcy or SAH) is also the immediate precursor of all of the homocysteine produced in the body. The reaction is catalyzed by S-adenosylhomocysteine hydrolase and is reversible with the equilibrium favoring formation of SAH. In vivo, the reaction is driven in the direction of homocysteine formation by the action of the enzyme adenosine deaminase which converts the second product of the S-adenosylhomocysteine hydrolase reaction, adenosine, to inosine. Except for methyl transfer from betaine and from methylcobalamin in the methionine synthase reaction, SAH is the product of all methylation reactions that involve S-adenosylmethionine (SAM) as the methyl donor. Methylation is significant in epigenetic regulation of protein expression via DNA and histone methylation. The inhibition of these SAM-mediated processes by SAH is a proven mechanism for metabolic alteration. Because the conversion of SAH to homocysteine is reversible, with the equilibrium favoring the formation of SAH, increases in plasma homocysteine are accompanied by an elevation of SAH in most cases. Disturbances in the transmethylation pathway indicated by abnormal SAH, SAM, or their ratio have been reported in many neurodegenerative diseases, such as dementia, depression, and Parkinsons disease (PMID:18065573, 17892439). Therefore, when present in sufficiently high levels, S-adenosylhomocysteine can act as an immunotoxin and a metabotoxin. An immunotoxin disrupts, limits the function, or destroys immune cells. A metabotoxin is an endogenous metabolite that causes adverse health effects at chronically high levels. Chronically high levels of S-adenosylhomocysteine are associated with S-adenosylhomocysteine (SAH) hydrolase deficiency and adenosine deaminase deficiency. S-Adenosylhomocysteine forms when there are elevated levels of homocysteine and adenosine. S-Adenosyl-L-homocysteine is a potent inhibitor of S-adenosyl-L-methionine-dependent methylation reactions. It is toxic to immature lymphocytes and can lead to immunosuppression (PMID:221926). S-adenosylhomocysteine, also known as adohcy or sah, is a member of the class of compounds known as 5-deoxy-5-thionucleosides. 5-deoxy-5-thionucleosides are 5-deoxyribonucleosides in which the ribose is thio-substituted at the 5position by a S-alkyl group. S-adenosylhomocysteine is slightly soluble (in water) and a moderately acidic compound (based on its pKa). S-adenosylhomocysteine can be found in a number of food items such as rapini, european plum, rambutan, and pepper (c. pubescens), which makes S-adenosylhomocysteine a potential biomarker for the consumption of these food products. S-adenosylhomocysteine can be found primarily in blood, cerebrospinal fluid (CSF), feces, and urine, as well as throughout most human tissues. S-adenosylhomocysteine exists in all living species, ranging from bacteria to humans. In humans, S-adenosylhomocysteine is involved in several metabolic pathways, some of which include phosphatidylcholine biosynthesis PC(14:0/18:3(9Z,12Z,15Z)), phosphatidylcholine biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/22:0), phosphatidylcholine biosynthesis PC(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)), and phosphatidylcholine biosynthesis PC(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)). S-adenosylhomocysteine is also involved in several metabolic disorders, some of which include 3-phosphoglycerate dehydrogenase deficiency, hawkinsinuria, non ketotic hyperglycinemia, and tyrosine hydroxylase deficiency. Moreover, S-adenosylhomocysteine is found to be associated with neurodegenerative disease and parkinsons disease. S-adenosylhomocysteine is a non-carcinogenic (not listed by IARC) potentially toxic compound. S-Adenosyl-L-homocysteine (SAH) is an amino acid derivative used in several metabolic pathways in most organisms. It is an intermediate in the synthesis of cysteine and adenosine . [Spectral] S-Adenosyl-L-homocysteine (exact mass = 384.12159) and Adenosine (exact mass = 267.09675) were not completely separated on HPLC under the present analytical conditions as described in AC$XXX. Additionally some of the peaks in this data contains dimers and other unidentified ions. [Spectral] S-Adenosyl-L-homocysteine (exact mass = 384.12159) and Cytidine (exact mass = 243.08552) were not completely separated on HPLC under the present analytical conditions as described in AC$XXX. Additionally some of the peaks in this data contains dimers and other unidentified ions. Acquisition and generation of the data is financially supported in part by CREST/JST. COVID info from PDB, Protein Data Bank, WikiPathways Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM[2]. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM[2].

   

4-(4-(Benzo[d][1,3]dioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl)benzamide

4-(4-(Benzo[d][1,3]dioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl)benzamide

C22H16N4O3 (384.1222)


   

(2S)-2-[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylamino]-4-sulfanylbutanoic acid

(2S)-2-[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylamino]-4-sulphanylbutanoic acid

C14H20N6O5S (384.1216)


   

UVA-1

2-{[3-(2H-1,2,3-benzotriazol-2-yl)-2-hydroxy-5-methylphenyl]methyl}-2,3-dihydro-1H-isoindole-1,3-dione

C22H16N4O3 (384.1222)


   

2-Methyl-9b-(1H-indole-3-yl)-2,4a,5-triaza-1,2,3,4,4a,4b,5,9b-octahydroindeno[2,1-a]indene-1,3,4-trione

2-Methyl-9b-(1H-indole-3-yl)-2,4a,5-triaza-1,2,3,4,4a,4b,5,9b-octahydroindeno[2,1-a]indene-1,3,4-trione

C22H16N4O3 (384.1222)


   
   

S-(5-Adenosyl)-L-homocysteine

S-(5-Adenosyl)-L-homocysteine

C14H20N6O5S (384.1216)


SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM[2]. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM[2].

   

S-Adenosyl-L-homocysteine

S-Adenosyl-L-homocysteine

C14H20N6O5S (384.1216)


An organic sulfide that is the S-adenosyl derivative of L-homocysteine. COVID info from PDB, Protein Data Bank, WikiPathways Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM[2]. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM[2].

   

S-Adenosyl-homocysteine

S-Adenosyl-homocysteine

C14H20N6O5S (384.1216)


   

S-Adenosylhomocysteine

S-Adenosylhomocysteine

C14H20N6O5S (384.1216)


SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM[2]. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM[2].

   

S-(5'-ADENOSYL)-L-HOMOCYSTEINE

S-(5'-ADENOSYL)-L-HOMOCYSTEINE

C14H20N6O5S (384.1216)


   

S-Adenosylhomocysteine (SAH); AIF; CE0; CorrDec

S-Adenosylhomocysteine (SAH); AIF; CE0; CorrDec

C14H20N6O5S (384.1216)


   

S-Adenosylhomocysteine (SAH); AIF; CE10; CorrDec

S-Adenosylhomocysteine (SAH); AIF; CE10; CorrDec

C14H20N6O5S (384.1216)


   

S-Adenosylhomocysteine (SAH); AIF; CE30; CorrDec

S-Adenosylhomocysteine (SAH); AIF; CE30; CorrDec

C14H20N6O5S (384.1216)


   

S-Adenosylhomocysteine (SAH); AIF; CE0; MS2Dec

S-Adenosylhomocysteine (SAH); AIF; CE0; MS2Dec

C14H20N6O5S (384.1216)


   

S-Adenosylhomocysteine (SAH); AIF; CE10; MS2Dec

S-Adenosylhomocysteine (SAH); AIF; CE10; MS2Dec

C14H20N6O5S (384.1216)


   

S-Adenosylhomocysteine (SAH); AIF; CE30; MS2Dec

S-Adenosylhomocysteine (SAH); AIF; CE30; MS2Dec

C14H20N6O5S (384.1216)


   

S-Adenosyl-homocysteine (SAH); LC-tDDA; CE10

S-Adenosyl-homocysteine (SAH); LC-tDDA; CE10

C14H20N6O5S (384.1216)


   

S-Adenosyl-homocysteine (SAH); LC-tDDA; CE20

S-Adenosyl-homocysteine (SAH); LC-tDDA; CE20

C14H20N6O5S (384.1216)


   

S-Adenosyl-homocysteine (SAH); LC-tDDA; CE30

S-Adenosyl-homocysteine (SAH); LC-tDDA; CE30

C14H20N6O5S (384.1216)


   

S-Adenosyl-homocysteine (SAH); LC-tDDA; CE40

S-Adenosyl-homocysteine (SAH); LC-tDDA; CE40

C14H20N6O5S (384.1216)


   

SB 431542

4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide

C22H16N4O3 (384.1222)


   

(2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid

(R)-2-AMINO-4-((((2S,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL)METHYL)THIO)BUTANOIC ACID

C14H20N6O5S (384.1216)


   

VU 29

VU 29

C22H16N4O3 (384.1222)


VU-29 is a positive allosteric modulator of metabotropic glutamate 5 (mGlu5) receptor (EC50=9 nM and Ki=244 nM for rmGluR5). VU-29 is selective for mGluR5 relative to other mGluR subtypes (EC50: rmGluR1/rmGluR2=557 nM/1.5 μM; hmGluR4=154 nM)[1][2].

   

dicyclohexyl sulfosuccinate sodium salt

dicyclohexyl sulfosuccinate sodium salt

C16H25NaO7S (384.1219)


   

5-S-[(3S)-3-azaniumyl-3-carboxylatopropyl]-5-thioadenosine

5-S-[(3S)-3-azaniumyl-3-carboxylatopropyl]-5-thioadenosine

C14H20N6O5S (384.1216)


   

S-formycinylhomocysteine

S-formycinylhomocysteine

C14H20N6O5S (384.1216)


   

(2S)-2-amino-4-[[5-(7-amino-2H-pyrazolo[4,3-d]pyrimidin-3-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid

(2S)-2-amino-4-[[5-(7-amino-2H-pyrazolo[4,3-d]pyrimidin-3-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid

C14H20N6O5S (384.1216)


   

(2S)-2-[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylamino]-4-sulfanylbutanoic acid

(2S)-2-[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylamino]-4-sulfanylbutanoic acid

C14H20N6O5S (384.1216)


   

SB431542

4-(4-(Benzo[d][1,3]dioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl)benzamide

C22H16N4O3 (384.1222)


   

S-adenosyl-L-homocysteine zwitterion

S-adenosyl-L-homocysteine zwitterion

C14H20N6O5S (384.1216)


Zwitterionic form of S-adenosyl-L-homocysteine arising from migration of a proton from the carboxy group to the alpha-amino group; major species at pH 7.3.

   

9-(1h-indol-3-yl)-5-methyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-7,10,12,14-tetraene-3,4,6-trione

9-(1h-indol-3-yl)-5-methyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-7,10,12,14-tetraene-3,4,6-trione

C22H16N4O3 (384.1222)


   

(2s)-2-amino-4-({[(2r,3r,4s,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl}sulfanyl)butanoic acid

(2s)-2-amino-4-({[(2r,3r,4s,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl}sulfanyl)butanoic acid

C14H20N6O5S (384.1216)


   

(1r,9s)-9-(1h-indol-3-yl)-5-methyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-7,10,12,14-tetraene-3,4,6-trione

(1r,9s)-9-(1h-indol-3-yl)-5-methyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-7,10,12,14-tetraene-3,4,6-trione

C22H16N4O3 (384.1222)


   

n-[(2e)-1-hydroxy-3-(quinolin-8-yl)prop-2-en-1-ylidene]-5-phenyl-1,2-oxazole-3-carbohydrazonic acid

n-[(2e)-1-hydroxy-3-(quinolin-8-yl)prop-2-en-1-ylidene]-5-phenyl-1,2-oxazole-3-carbohydrazonic acid

C22H16N4O3 (384.1222)